Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide versus fluticasone intranasal sprays in children with allergic rhinitis
ACTRN12613001148763Phase 3Not yet recruiting
- Sponsor
- Mater
- Start
- Nov 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of budesonide and fluticasone in allergic rhinitis (AR) (2 arms), sponsored by Mater. Primary endpoint: Patient preference for one of the two medications. Planned start Nov 2013; status: not yet recruiting.
02
Drugs
budesonidefluticasone
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on ACTRN12613001148763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613001148763.